# Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

> **NCT02167958** · PHASE1 · COMPLETED · sponsor: **Rafic Farah, MD** · enrollment: 28 (actual)

## Conditions studied

- Leukemia
- MDS
- Myelofibrosis
- Lymphoma

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Mesna
- **RADIATION:** Total Body Irradiation
- **OTHER:** Hematopoietic stem cell infusion
- **DRUG:** Tacrolimus
- **DRUG:** Mycophenolate
- **DRUG:** G-CSF

## Key facts

- **NCT ID:** NCT02167958
- **Lead sponsor:** Rafic Farah, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-11
- **Primary completion:** 2019-09-21
- **Final completion:** 2019-09-21
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2019-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02167958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02167958, "Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02167958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*